Using DNA tests to guide chemotherapy after bladder cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You had surgery to remove your bladder or upper urinary tract with lymph nodes.
- Your cancer was muscle-invasive and mostly transitional cell type.
- You must be in good enough health for chemotherapy, with normal blood counts and kidney function.
- You can't have had other cancer treatments in the past 3 weeks or be in another trial right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.